-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Further Weakness as Health Catalyst (NASDAQ:HCAT) Drops 15% This Week, Taking One-year Losses to 83%
Further Weakness as Health Catalyst (NASDAQ:HCAT) Drops 15% This Week, Taking One-year Losses to 83%
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and hard about avoiding extreme losses. So we hope that those who held Health Catalyst, Inc. (NASDAQ:HCAT) during the last year don't lose the lesson, in addition to the 83% hit to the value of their shares. That'd be a striking reminder about the importance of diversification. Even if you look out three years, the returns are still disappointing, with the share price down71% in that time. Furthermore, it's down 46% in about a quarter. That's not much fun for holders. While a drop like that is definitely a body blow, money isn't as important as health and happiness.
With the stock having lost 15% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
See our latest analysis for Health Catalyst
Given that Health Catalyst didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last year Health Catalyst saw its revenue grow by 23%. That's definitely a respectable growth rate. Unfortunately, the market wanted something better, given it sent the share price 83% lower during the year. It could be that the losses are too much for investors to handle without losing their nerve. We'd posit that the future looks challenging, given the disconnect between revenue growth and the share price.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
NasdaqGS:HCAT Earnings and Revenue Growth September 23rd 2022It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So we recommend checking out this free report showing consensus forecasts
A Different Perspective
The last twelve months weren't great for Health Catalyst shares, which performed worse than the market, costing holders 83%. Meanwhile, the broader market slid about 20%, likely weighing on the stock. Shareholders have lost 19% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges. We would be wary of buying into a company with unsolved problems, although some investors will buy into struggling stocks if they believe the price is sufficiently attractive. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Health Catalyst you should be aware of.
Health Catalyst is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
正如每个投资者都知道的那样,你不会每次挥杆都打出本垒打。但认真的投资者应该深思熟虑,避免极端的损失。所以我们希望那些持有Health Catalyst,Inc.纳斯达克(Sequoia Capital:HCAT)在过去一年中,除了股价暴跌83%之外,不要失去教训。这将是一个引人注目的提醒,提醒人们多元化的重要性。即使你放眼三年,回报仍然令人失望,股价在这段时间里下跌了71%。此外,它在大约四分之一的时间里下跌了46%。对于持有者来说,这并不是什么乐趣。虽然像这样的下降绝对是对身体的打击,但金钱并不像健康和幸福那么重要。
鉴于该公司股价在过去一周下跌了15%,我们有必要看看公司的业绩,看看是否有什么危险信号。
查看我们对Health Catalyst的最新分析
鉴于Health Catalyst在过去12个月中没有盈利,我们将重点关注收入增长,以快速了解其业务发展。当一家公司没有盈利时,我们通常预计会看到良好的收入增长。正如你可以想象的那样,快速的收入增长,如果保持下去,往往会带来快速的利润增长。
去年,Health Catalyst的收入增长了23%。这绝对是一个相当可观的增长率。不幸的是,市场想要更好的东西,因为这导致该公司股价在年内下跌了83%。这可能是因为损失太大,让投资者在处理这些损失时不会失去勇气。我们认为,考虑到收入增长和股价之间的脱节,未来看起来充满挑战。
下图显示了收益和收入随时间的变化情况(如果您点击该图,您可以看到更多详细信息)。
NasdaqGS:HCAT收益和收入增长2022年9月23日可能值得注意的是,我们在上个季度看到了大量的内幕收购,我们认为这是一个积极的因素。尽管如此,我们认为收益和收入增长趋势是更重要的考虑因素。因此,我们建议您查看以下内容免费显示共识预测的报告
不同的视角
过去12个月对Health Catalyst的股价来说并不好,其表现逊于大盘,持有者损失了83%。与此同时,大盘下跌约20%,可能令该股承压。股东在过去三年里每年损失19%,因此股价在过去一年里跌幅变得更大;这是尚未解决的挑战的潜在症状。我们会对买入一家问题尚未解决的公司持谨慎态度,尽管一些投资者如果认为价格足够有吸引力,就会买入陷入困境的股票。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。一个恰当的例子:我们发现了Health Catalyst的3个警告信号你应该意识到。
Health Catalyst并不是业内人士唯一买入的股票。所以让我们来看看这个免费内幕收购的成长型公司名单。
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧